Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
O
039200
vs
K
KOSPI 200
Over the past 12 months, Oscotec Inc has underperformed KOSPI 200, delivering a return of -19% compared to KOSPI 200's +125% growth.
Stocks Performance
039200 vs KOSPI 200
Performance Gap
039200 vs KOSPI 200
Performance By Year
039200 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oscotec Inc
Glance View
Oscotec Inc is a South Korean biotechnology company that discovers and develops new medicines. Its work centers on drug candidates for diseases such as cancer, autoimmune conditions, and other serious illnesses, moving them through preclinical and clinical testing. The company does not run a broad consumer business; it focuses on building pharmaceutical assets that can become approved therapies or be partnered with larger drugmakers. The company makes money mainly by advancing its drug pipeline and by working with other pharmaceutical companies through licensing, research collaboration, and technology transfer deals. In this model, customers are usually not end patients but drug partners, hospitals, and eventually healthcare providers that may use the finished medicines if development succeeds. That means Oscotec’s value depends heavily on the quality of its patents, scientific data, and clinical results. What makes Oscotec’s business different is that it sits at the high-risk, high-reward stage of drug development. Instead of selling a finished product line, it creates intellectual property and drug candidates that can be licensed or developed into approved treatments. For beginner investors, the key idea is that Oscotec is a research-driven biotech company whose business is built around discovering medicines and turning that science into commercial drug rights.